Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

LifePort Inc. Signs Two Agreements Launching Company Into Mission-Specific Seating

October 19, 2010 10:33 am | by Bio-Medicine.Org | News | Comments

ATLANTA, Oct. 19 /- NBAA Trade Show -- LifePort Inc. today announced the signing of two agreements that launch the company into customized mission-specific seating. LifePort is a Sikorsky Aerospace Services (SAS) company – the aftermarket division of Sikorsky Aircraft Corp., a...

TOPICS:

Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium

October 19, 2010 10:33 am | by Bio-Medicine.Org | News | Comments

COLUMBIA, Md., Oct. 19 /- Celsion Corporation (Nasdaq: CLSN ) announced today that two abstracts on the ThermoDox® High Intensity Focused Ultrasound (HIFU) development program have been delivered via oral presentation at the MR-guided Focused Ultrasound 2010 2nd International...

TOPICS:

GTC Biotherapeutics gets $17M offer to go private

October 19, 2010 9:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

GTC Biotherapeutics Inc., a Framingham biotechnology firm that has seen its operational funds dwindle and several employees laid off earlier this year, has received a $17 million offer from French strategic partner LFB Biotechnologies to take GTC private.

Advertisement

Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease

October 19, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 19 /- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic...

TOPICS:

Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe

October 19, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

LAGUNA NIGUEL, Calif., Oct. 19 /- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.  Expected to enter pivotal clinical trials before the end of this year, OBI-1 is...

TOPICS:

TYRX AIGISRx antibacterial envelope shows low infection rate, high CIED procedure success

October 19, 2010 8:34 am | by EurekAlert | News | Comments

(Kureczka/Martin Associates) COMMAND study results showed that patients undergoing CIED (cardiac implantable electronic device) implantation with TYRX Inc.'s FDA-cleared AIGISRx Antibacterial Envelope enjoyed a 99.5 percent rate of successful implantation with an overall infection...

TOPICS:

Where Should Companies Innovate? In Their Enterprises.

October 19, 2010 8:32 am | by Bio-Medicine.Org | News | Comments

CENTER VALLEY, Pa., Oct. 19 /- Olympus Corporation of the Americas ( www.olympusamerica.com ) today released findings from a Harris Interactive survey of Fortune 1000 executives concerning enterprise innovation – defined as the transformative business processes, practices,...

TOPICS:

Sysmex America Announces Amerinet Hematology Contract

October 19, 2010 8:31 am | by Bio-Medicine.Org | News | Comments

MUNDELEIN, Ill., Oct. 19 /- Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced a three-year, dual source hematology contract agreement with Amerinet. Amerinet members have immediate purchasing/leasing access to Sysmex...

TOPICS:
Advertisement

Opto Circuits to buy Cardiac Science for $64M

October 19, 2010 7:45 am | by The Associated Press | News | Comments

Heart diagnostics company Cardiac Science Corp. said Tuesday it is being bought by Opto Circuits Ltd. for about $64 million cash in a tender offer.The company said Opto Circuits, based in India, is paying $2.30 per share, marking a 10 percent premium to Cardiac Sciences closing price of $2.10...

AC-DC Power Supplies Are Compact, Offer High Efficiency

October 19, 2010 7:36 am | XP Power | Product Releases | Comments

These highly efficient units, typically up to 91%, comprise four output power models: a 650 W and 1.0 kW, which are both less than 1 U high, and a 1.5 and 3.0 kW.

MIT Desphande Center awards $800K in grants

October 19, 2010 7:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

The MIT Deshpande Center today announced $800,000 in new grants for research efforts at MIT. The grants went to 11 researchers, with most in the life sciences and medical devices industry, in addition to energy and information technology.

MultiCell's Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets

October 19, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

WOONSOCKET, R.I., Oct. 19 /- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET ) and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western...

TOPICS:

Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors

October 19, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 19 /- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD ), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that Rod Kenley has been appointed to the Aethlon Medical board of directors. (Photo:...

TOPICS:

Baltimore to Host Largest Gathering of Cystic Fibrosis Scientists and Clinicians in the World

October 19, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

BETHESDA, Md., Oct. 19 /PRNewswire-USNewswire/ -- In the largest meeting of its kind, nearly 4,000 doctors, scientists, researchers and caregivers will meet in Baltimore, Md., Oct. 21 –23, 2010, to present the latest information and advancements on cystic fibrosis (CF) drug...

TOPICS:

Pencil Beam Radiation Offers New Therapy Option for Lung Cancer Patients

October 19, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

HOUSTON, Oct. 19 /- Pencil beam scanning technology, an even more advanced and targeted form of radiation treatment known as proton therapy, is now being used to treat patients with lung cancer at The University of Texas MD Anderson Cancer Center.   Proton therapy derives its...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading